Sangye Menla Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 28-06-2024
- Paid Up Capital ₹ 1.00 M
as on 28-06-2024
- Company Age 4 Year, 13 Days
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2022)
- Profit 99.29%
(FY 2022)
- Ebitda 99.29%
(FY 2022)
- Net Worth -0.29%
(FY 2022)
- Total Assets -29.10%
(FY 2022)
About Sangye Menla Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Manoranjan Rout, Dharitri Patnaik, and Parthiv Mehta serve as directors at the Company.
- CIN/LLPIN
U24296OR2020PTC035040
- Company No.
035040
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Dec 2020
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Khorda, Odisha, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sangye Menla Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoranjan Rout  | Director | 09-Dec-2020 | Current |
| Dharitri Patnaik | Director | 09-Dec-2020 | Current |
| Parthiv Mehta | Director | 09-Dec-2020 | Current |
Financial Performance of Sangye Menla Pharmaceuticals.
Sangye Menla Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 99.29% increase in profit. The company's net worth dipped by a decrease of 0.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sangye Menla Pharmaceuticals?
Unlock access to Sangye Menla Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Diversified Energy Solutions Private LimitedActive 15 years 9 monthsDharitri Patnaik and Parthiv Mehta are mutual person
Carina Infratech Private LimitedActive 2 years 10 monthsDharitri Patnaik and Parthiv Mehta are mutual person
- Silvanus Consultancy Services Private LimitedActive 2 years 7 months
Dharitri Patnaik and Parthiv Mehta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sangye Menla Pharmaceuticals?
Sangye Menla Pharmaceuticals has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sangye Menla Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sangye Menla Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
